Key facts
- It has raised $520K.
- Notable investors include AXOLOTL (Germany), Gateway Accelerator, High-Tech.NRW, Start2grow.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for VitrofluidiX
- ·The full record, as it builds
Funding rounds
No funding rounds for VitrofluidiX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VitrofluidiX
Developer of an organ-on-a-chip platform designed to simulate human organ functions for research and testing. The company's platform offers integrated hardware and software with automated and imaging-compatible systems, enabling pharmaceutical companies and research institutions to conduct predictive testing and study biological processes.
- Sector
- Healthcare
- HQ
- Cologne, Germany
- Founded
- 2021
- Employees
- 6
- Website
- vitrofluidix.com/
- Ownership
- Privately Held (backing)
VitrofluidiX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VitrofluidiX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VitrofluidiX in its N-PORT filings yet. We sweep new filings monthly.